Rajni Miglani Bhardwaj is Associate Research Fellow at Pfizer. She completed her undergraduation in pharmacy at MD University, India (2003), masters in medicinal chemistry at NIPER, India (2005) and...
By Dr. Susan M. Reutzel-Edens, Ph.D. FRSC President, SuRE Pharma Consulting, LLC Drug product design generally begins with identifying, oftentimes through experimental crystallization screening, solid forms in which to...
Dr. Susan M. Reutzel-Edens, President of SuRE Pharma Consulting, LLC, earned her Ph.D. in Chemistry at the University of Minnesota under the direction of the late Professor Margaret C....
By Dr. Olexandr Isayev, Ph.D. Associate Professor, Carnegie Mellon University Machine learned interatomic potentials (MLIPs) are reshaping computational chemistry practices because of their ability to drastically exceed the...
Olexandr Isayev is an Associate Professor at the Department of Chemistry at Carnegie Mellon University. In 2008, Olexandr received his Ph.D. in computational chemistry. He was a Postdoctoral Research Fellow at Case...
By Dr. Daniela Blanco, Ph.D., CEO and Co-Founder, Sunthetics Pharmaceutical crystallizations, as well as process and product development present significant challenges in terms of cost, efficiency, and sustainability. Harnessing...
By Dr. Jeremy M. Merritt, Ph.D. Senior director and Group leader, Eli Lilly & Co. Automation plays a vital role in reducing development time in the pharmaceutical industry, both...
Jeremy M. Merritt (merrittje@lilly.com) is currently a Senior director and group leader at Eli Lilly and Co. in the synthetic molecule design and development organization (SMDD). He joined Lilly...
